Alnylam Pharmaceuticals (ALNY) hit a new 52-week high on Monday after it reported positive top-line results from a late-stage study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic, for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The stock jumped 34.5% in response to the success of the study. Please note that Amvuttra is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. It is ...